Natera beats Q2 revenue estimates, shares jump 16% after hours

Natera's Q2 revenue rose about 38% to approximately $753M, beating estimates, and shares jumped 16% after hours to $308. The diagnostics company processed over 1.04 million tests, a quarterly record, and oncology MRD volumes rose 56%. Management raised full-year 2026 revenue guidance to $2.85B-$2.91B, citing stronger margins and regulatory wins. The stock had closed down 3.36% at $265.38 before the after-hours surge above its 52-week high of $288.04. Natera expects continued positive cash flow and future Signatera pricing gains in 2027.